CeQur® announced that the company has appointed Bradley Paddock as chief executive officer, effective today. Paddock brings a track record of commercial medtech successes, notably leading sales up to $600 million during his eight-year tenure at Kyphon, Inc. Paddock also managed successful commercial operations for multiple industry-leading companies, including Stryker, Bausch + Lomb, Inc., and Medtronic, Inc.
CeQur Appoints Peter B. Luther to Board of Directors
CeQur® announced the appointment of Peter B. Luther to its board of directors, effective immediately. Luther is a 29-year veteran of the medical device and diagnostics, OTC drugs and consumer-packaged goods industries.
Keywords: Advisor, CeQur, Commercialization, PAQ MEAL, PAQ TOTAL
Published in JDST how CeQur's PAQ Insulin Delivery Device Overcomes Barriers
The Journal of Diabetes Science and Technology paper summarizes data from multiple studies of the PAQ basal-bolus insulin delivery device and how it helps overcome barriers to insulin delivery to meet the needs of people with type 2 diabetes and their healthcare providers.
Data Published in JHEOR Demonstrate the Cost-Effectiveness of CeQur PAQ Insulin Delivery Device
The Journal of Health Economics and Outcomes Research published findings from a long-term cost-effectiveness evaluation of continuous subcutaneous insulin infusion (CSII) with CeQur’s PAQ® Insulin Delivery Device as compared to multiple daily insulin injections (MDI) for people with type 2 diabetes.
Data Published in Diabetic Medicine Demonstrate the CeQur PAQ Insulin Delivery Device Improved Glycemic Control
CeQur® today announced that the journal Diabetic Medicine published the findings from two studies evaluating the company’s PAQ® Insulin Delivery Device among people with type 2 diabetes. The data demonstrate that the simple three-day, wearable PAQ basal-bolus insulin delivery device significantly improved glycemic control among people with type 2 diabetes who transitioned to the device. Study participants also reported increased treatment satisfaction with the PAQ basal-bolus insulin device as compared to insulin injections.
CeQur® today announced that the company has acquired select assets of Calibra Medical, Inc., one of the Johnson & Johnson Diabetes Care Companies. The transaction includes an exclusive worldwide license for the wearable, on-demand insulin delivery system previously known as OneTouch Via™. The Calibra system enables people with diabetes to discreetly and conveniently deliver rapid-acting insulin at mealtime.
CeQur Appoints Robert Farra Chief Executive Officer
Farra has a more than 30-year record of leading organizations in the development of novel products, including drug delivery devices, medical devices, and sensors in the diabetes, cardiac, and surgical fields. Prior to joining CeQur, he was with Microchips Biotech, a developer of wirelessly-enabled drug delivery and sensing implants, where he held senior roles including president, chief technology officer, and vice president of R&D. Farra has extensive expertise and medtech capabilities that are essential to CeQur, including electro-mechanical and fluidic- based medical devices, drug delivery technologies and automation equipment.
CeQur Wins Medtech Wearable Award at 2016 Tech Tour Healthtech Summit
The Healthtech Summit 2016 Advisory Board and Team reviewed a number of excellent nominations for the Digital Health and Medtech Award, and CeQur was honored to be selected as the Winner of the Medtech Award 2016; recognizing PAQ as a technology that will free many of those with type 2 diabetes from the burden of daily insulin injections!
CeQur will use the new funds to support further clinical and regulatory activities, manufacturing scale-up and commercial operations for the 2016 first commercial launch of PAQ®, the Company’s fully optimized second-generation three-day insulin infusion device.
Health Tech Insider, May 2015: Device Delivers Insulin Automatically
This article highlights how CeQur’s PAQ Simple Insulin Delivery Device can help address the barriers associated with daily insulin injection for people with type 2 diabetes. It includes a link to a video demonstrating how PAQ works. Copyright 2015 Center Ring Media LLC
CeQur Announces Publication of Data Demonstrating PaQ® Insulin Delivery Device
Reduces Barriers to Insulin Therapy
CeQur Announces Publication of Data Demonstrating PAQ® Insulin Delivery Device Reduces Barriers to Insulin Therapy - Study results published in Journal of Diabetes Science and Technology. CeQur SA, a leader in simple infusion for people with diabetes, announced that results from a clinical study evaluating the company’s PAQ® Insulin Delivery Device appear in this month’s Journal of Diabetes Science and Technology. The data demonstrate that switching to the PAQ device from multiple-daily insulin injections (MDI) can help people with type 2 diabetes overcome barriers to insulin therapy and negative appraisal of insulin treatment without increasing diabetes-related distress.
In its January 2014 issue, Diabetes Forecast selected PAQ among seven diabetes products that are “poised to make waves in the diabetes world.” The magazine’s annual consumer quide highlighted PAQ as a new option for people who “don’t require the added features traditional pumps provide but whose blood glucose control might benefit from continuous insulin infusion.”
Diabetes blogger Alex O’Meara included PAQ among his list of highly anticipated diabetes advances for 2014. “The new technologies and treatments making their appearance in 214 means it will be an exciting year in diabetes care and management,” Alex notes.
MedGadget, June 2013: Continued Advancement for Diabetic Therapies – An Interview with CeQur SVP Jay Warner
CeQur Senior Vice President of Commercialization discusses why there is a substantial need for simple insulin delivery devices like PAQ, why PAQ is different than other insulin delivery and mentions the clinical data that has and will be released and future plans for the device.
CeQur Named Among FierceMedicalDevices 2013 "Fierce 15"
Industry-leading organization and publication FierceMedicalDevices selected CeQur as one of 2013 "Fierce 15" device and diagnostic companies, designating the company as one of the most promising private companies in the med tech space. The publication evaluates companies from around the world for its annual list, which is based on factors including technology strength, partnerships, venture backers, and competitive market position. "We have the opportunity to ... come in and target a space and make a huge difference in people's lives. It's going to be a really big deal" said CeQur CEO Jim Peterson in the resulting Fierce story.
Start Up magazine, January 2010: CeQur makes the "A-List"
In this review of the 2009 biopharma financing environment, Start Up writers Christopher Morrison and Tom Salemi selected CeQur from among the 60 Series A financings that occurred last year as one of just 13 they consider “trend-shaping”. Morrison and Salemi note that CeQur and its 12 “A-list” peers are companies to “keep an eye on in 2010 and beyond.”
Massachusetts Medical Device Journal, January 2010: Q&A with CeQur CEO Jim Peterson
CeQur CEO Jim Peterson discusses his personal ties to diabetes technologies, why CeQur is poised to be the leader in next-generation insulin delivery devices, and why the CeQur PAQ insulin infuser will provide a unique, simple solution to many of the treatment challenges faced by people with type II diabetes. Peterson spoke with MassDevice just before giving a presentation on the patch-like device CeQur is developing for insulin delivery at the OneMedPlace Finance Forum in San Francisco Jan 13, 2010. He told us about the personal connection he feels to his current work, which stems from the fact that his daughter has diabetes, and why he sees Montreux, Switzerland-based CeQur’s device as a potential market leader.